Bibliography
- Data was obtained from the World Health Organization. Available from: http://www.who.int/diabetes/en/ [Last accessed 10 December 2008]
- Data was obtained from the World Health Organization. Available from: http://www.who.int/infobase/compare.aspx?dm = 5&countries = 76%2c124%2c156%2c356%2c566%2c586%2c643%2c826%2c834%2c840&year = 2005&sf1 = cd.0701&sex = all&agegroup = 15-100 [Last accessed 10 December 2008]
- Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Cardiovasc Renal 2005;9:267-81
- Tong L, Harwood HJ Jr. Acetyl-CoA carboxylases: versatile targets for drug discovery. J Cell Biochem 2006;99:1476-88
- Harwood HJ Jr, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003;278:37099-111
- Zhang H, Tweel B, Li J, Tong L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. Structure 2004;12:1683-91
- Harada N, Oda Z, Hara Y, et al. Hepatic de novo lipogenesis is present in liver-specific ACC-1 deficient mice. Mol Cell Biol 2007;27:1881-8
- Abu-Elheiga L, Matzuk MM, Kordari P, et al. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci 2005;102:12011-6
- Clark RF, Zhang T, Xin Z, et al. Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity. Bioorg Med Chem Lett 2006;16:6078-81
- Gu YG, Weitzberg M, Clark RF, et al. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors. J Med Chem 2006;49:3770-3
- Xu X, Weitzberg M, Keyes RF, et al. The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: Polar region modifications. Bioorg Med Chem Lett 2007;17:1803-7
- Clark RF, Zhang T, Wang X, et al. Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: modulation of isozyme selectivity by incorporation of phenyl ring substituents. Bioorg Med Chem Lett 2007;17:1961-5
- Corbett JW, Harwood HJ Jr. Inhibitors of mammalian acetyl-CoA carboxylase. Rec Patents Cardiovasc Drug Discov 2007;2:162-80
- Fukatsu K, Kamata M, Yamashita T, Endo S. Nitrogen-containing heterocyclic compound. WO07119833; 2007
- Fukatsu K, Kamata M, Yamashita T. Spiro-ring compound. WO08090944; 2008
- Kamata M, Fukatsu K, Yamashita T, et al. Spiro-cyclic compound. WO07013691; 2007
- Chang E, McNeill MH. Acetyl-CoA carboxylase inhibitors. WO08121592; 2008
- Hiradate A, Osanami T, Oi T, et al. Preparation of piperazine derivatives as acetyl-CoA carboxylase inhibitors. JP2008179621; 2008
- Corbett JW, Elliott RL, Bell A. Spiroketone acetyl-CoA carboxylase inhibitors. WO08065508; 2008
- Iino T, Jona H, Shibata J, et al. Substituted spirochromanone derivatives as ACC inhibitors. WO08088688; 2008
- Iino T, Jona H, Shibata J, et al. Substituted spirochromanone derivatives as ACC inhibitors. WO08088689; 2008
- Iino T, Jona H, Kurihara H, et al. Spirochromanon derivatives. WO08088692; 2008
- Fukatsu K, Kamata M, Yamashita T. Heterocyclic compound. WO08102749; 2008
- Shen Y, Volrath SL, Weatherly S, et al. Crystal structure of biotin carboxylase (BC) domain of acetyl-coenzyme A carboxylase and methods of use thereof. WO06017515; 2006
- Hokama T, Lee S-F, et al. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof. US20080200461; 2008
- Anderson R, Lee S-F, Oey R, et al. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof. WO08103354; 2008
- Gu YG, Weitzberg M, Clark RF, et al. N-{3-[2-(4-Alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-CoA carboxylase inhibitors – Improvement of cardiovascular and neurological liabilities via structural modifications. J Med Chem 2007;50:1078-82
- Gu YG, Xu X, Weitzberg M, et al. Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome. WO07095603; 2007
- Gu YG, Clark RF, Li Q, et al. Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome. WO08079610; 2008
- Keyes RF, Gu YG, Sham HL. Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome. WO07095601; 2007
- Hong YD, Kang S-H, Kim Y, et al. Triazolopyridazine derivatives having inhibitory activity against acetyl-CoA carboxylase. WO08069500; 2008
- Information obtained from “Profile and Collaboration Agenda of Leading Pharmaceutical & Biotechnology Companies in Korea”: Issued by the Korea Drug Research Association (2006). Available from: http://www.mediconvalley.com/pdf/Korean%20Pharmaceutical%20Company%20Profile(060905).pdf [Last accessed 12 December 2008]
- Cho YS, Lee JI, Shin D, et al. Crystal structure of the biotin carboxylase domain of human acetyl-CoA carboxylase 2. Proteins 2007;70:268-72
- Joo YH, Kang S-H, Hong YD, et al. Triazine derivatives having inhibitory activity against acetyl-CoA carboxylase. WO08072850; 2008
- Kozmin S, Cui J, Haselkorn R, Gornicki P. Method for assembling high-purity chemical libraries, compounds suppressing acetyl-CoA carboxylase activities discovered by same. WO08103382; 2008
- Henderson ST. Inhibitors of acetyl-CoA carboxylase for treatment of hypometabolism. WO08140828; 2008
- Perry DA, Harwood HJ Jr. Acetyl-CoA carboxylase inhibitors. US6979741; 2005
- Waldrop GL, Stephens JM, Levert KL. Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies. US6485941; 2002
- Beutel BA, Camp HS, Clark RF, et al. Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome. US060178400; 2006
- Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-1